Study Highlights Benefits of Ketogenic Diet Training for Mental Health Professionals
A recent study from the University of Maryland highlights that an experiential training program can enhance health care professionals’ confidence in employing ketogenic dietary therapies for mental health treatments. While initial findings are promising, further research is necessary to confirm these results in clinical practice.
Promising Insights from Ketogenic Metabolic Therapy
Ketogenic metabolic therapy, characterized by a high-fat, low-carbohydrate diet, has shown potential in alleviating symptoms of certain mental illnesses. A study published in the journal Frontiers in Psychiatry by researchers at the University of Maryland School of Medicine’s Maryland Psychiatric Research Center (MPRC) examined the impact of a specialized training program on health care professionals’ readiness to use this dietary approach.
The ketogenic diet typically includes approximately 75% of calories from fats, around 20% from proteins, and less than 10% from carbohydrates. This dietary shift encourages the body to use ketones instead of glucose, a change that researchers believe could benefit patients with neurological and psychiatric disorders that do not respond to standard treatments.
The ketogenic diet typically includes approximately 75% of calories from fats, around 20% from proteins, and less than 10% from carbohydrates.
Training Program Details and Participant Experience
The study involved a pilot program that trained 40 health care professionals across various specializations, including psychiatrists, psychologists, and therapists. Participants engaged in a four-hour online course that introduced them to the principles of ketogenic metabolic therapy, highlighting dietary strategies, monitoring, and potential adverse effects.
In a unique component of the training, 25 participants opted to follow the ketogenic diet for four weeks, allowing them to experience the dietary changes firsthand under guidance from registered dietitians and nutrition specialists. This immersive approach significantly boosted their confidence in discussing the diet’s benefits and challenges with their patients.
Considerations and Future Research Directions
Deanna L. Kelly, PharmD, BCPP, who led the study, noted the importance of equipping clinicians with both knowledge and practical experience. The research emphasizes that while the initial data is encouraging, it is merely a starting point. Longer-term studies and randomized controlled trials are essential to ascertain the efficacy and clinical applicability of ketogenic diets in mental health care.
Moreover, the implications of the ketogenic diet extend beyond mental health benefits. As Dr. Kelly pointed out, many patients with conditions like schizophrenia often face metabolic issues exacerbated by antipsychotic medications. Finding therapeutic diets that support metabolic health may represent a significant advance in holistic patient care.
THE CNP TAKEAWAY
Healthcare professionals may find increased confidence in utilizing ketogenic diets to support mental health treatments after receiving experiential training. However, ongoing research is essential to validate these findings and assess practical applications in clinical settings.
Sources & References
Original News Source
University of Maryland School of Medicine. New UMSOM Research Shows Promising Results for Health Care Professionals Using Ketogenic Diet Therapy to Treat Mental Illness
Additional Research & CNP References
-
Gao, M., Kirk, M., Knight, H., Lash, E., Michalopoulou, M., Guess, N., Stevens, R., Browning, M., Weich, S., Burnet, P. W. J., Jebb, S. A., & Aveyard, P. (2026). A Ketogenic Diet for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA psychiatry, 83(4), 331–340. https://doi.org/10.1001/jamapsychiatry.2025.4431
-
Abram, S. V., Kyner, J. M., Vu, A., Naeem, Z., Sethi, S., Jacob, M. S., Fryer, S. L., Mathalon, D. H., & Ford, J. M. (2026). Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial. Schizophrenia Bulletin, 52(4). https://doi.org/10.1093/schbul/sbag082
